Back to discover
Drug

Linzagolix choline

Approved medicine
RxNorm2621020
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Linzagolix choline
RxNorm CUI
2621020
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2022-06-14
Latest approval
2022-06-14
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2022-06-14Original application approval
Marketing authorisation: Yselty (EMA)
Indication: Yselty is indicated in adult women of reproductive age for: -           treatment of moderate to severe symptoms of uterine… Show full indication

Yselty is indicated in adult women of reproductive age for: -           treatment of moderate to severe symptoms of uterine fibroids,-           symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.